Page 8«..78910..2030..»

Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual…

Posted: December 7, 2024 at 2:50 am

– SAFETY: NRTX-1001 has been well-tolerated to date at both high and low doses. No adverse events have been attributed to the cell therapy

Read more here:
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual...

Posted in Global News Feed | Comments Off on Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual…

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in…

Posted: December 7, 2024 at 2:50 am

A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies

Follow this link:
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in...

Posted in Global News Feed | Comments Off on Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in…

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites…

Posted: December 7, 2024 at 2:50 am

Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings A/S.

More:
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites...

Posted in Global News Feed | Comments Off on The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites…

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Posted: December 7, 2024 at 2:50 am

ZUG, Switzerland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Read the original here:
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Posted in Global News Feed | Comments Off on Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

Posted: December 7, 2024 at 2:50 am

Paves way for additional large indications markets Paves way for additional large indications markets

Go here to read the rest:
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

Posted in Global News Feed | Comments Off on NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of…

Posted: December 7, 2024 at 2:50 am

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag

Originally posted here:
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of...

Posted in Global News Feed | Comments Off on BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of…

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s…

Posted: December 7, 2024 at 2:50 am

BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association’s 35th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada.

See the rest here:
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s...

Posted in Global News Feed | Comments Off on Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s…

Georgiamune Appoints Biopharma Veteran Mark Avagliano as Chief Business Officer to Drive Growth

Posted: November 20, 2024 at 2:48 am

GAITHERSBURG, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announces the appointment of Mark Avagliano as Chief Business Officer. The news comes as Georgiamune closes out 2024 after having initiated three assets into clinical trials. With Phase 2 testing ambitions set for 2025 across the three clinical assets in both cancer and autoimmune diseases (GIM-122, GIM-531 and GIM-407), Avagliano’s combination of business acumen and sector expertise will further empower the company to meet these pivotal milestones while ensuring that its robust earlier stage pipeline progresses through development.

Here is the original post:
Georgiamune Appoints Biopharma Veteran Mark Avagliano as Chief Business Officer to Drive Growth

Posted in Global News Feed | Comments Off on Georgiamune Appoints Biopharma Veteran Mark Avagliano as Chief Business Officer to Drive Growth

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Posted: November 20, 2024 at 2:48 am

Conference being held November 19-21, 2024 Conference being held November 19-21, 2024

Read more here:
Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Posted in Global News Feed | Comments Off on Relmada Therapeutics to Present at Jefferies London Healthcare Conference

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

Posted: November 20, 2024 at 2:48 am

NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy

Go here to read the rest:
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

Posted in Global News Feed | Comments Off on MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

Page 8«..78910..2030..»